PHAXIAM Therapeutics S.A.
Euronext ParisTotal Valuation
PHAXIAM Therapeutics S.A. carries a market capitalization of 1.01M, placing it among publicly traded companies globally. Its enterprise value stands at -13.89M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.01M |
| Enterprise Value | -13.89M |
Share Statistics
PHAXIAM Therapeutics S.A. currently has 3.36M shares outstanding.
| Shares Outstanding | 3.36M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 3.96 |
| P/TBV Ratio | 0.48 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
| EV / Sales | N/A |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 270.18 |
Financial Position
PHAXIAM Therapeutics S.A. maintains a current ratio of 3.65, meaning it holds 3.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 57.77, indicating elevated leverage, while an interest coverage ratio of -85.10 demonstrates limited ability to service its debt obligations.
| Current Ratio | 3.65 |
| Quick Ratio | 3.55 |
| Debt / Equity | 57.77 |
| Debt / EBITDA | -0.50 |
| Interest Coverage | -85.10 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -0.41 |
| Return on Invested Capital (ROIC) | 49.55 |
| Return on Capital Employed (ROCE) | 10.73 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
Over the trailing twelve months, PHAXIAM Therapeutics S.A. has paid 521,000.00 in income taxes, reflecting an effective tax rate of 177.82.
| Income Tax | 521,000.00 |
| Effective Tax Rate | 177.82 |
Stock Price Statistics
PHAXIAM Therapeutics S.A.'s stock has declined approximately -94.975% over the past 52 weeks. The 50-day moving average sits at 0.19, while the 200-day moving average is 1.19.
| Beta (5Y) | N/A |
| 52-Week Price Change | -94.975% |
| 50-Day Moving Average | 0.19 |
| 200-Day Moving Average | 1.19 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -27.15M, while operating income came in at -27.15M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -27.15M |
| Pretax Income | 293,000.00 |
| Net Income | -228,000.00 |
| EBITDA | -27.15M |
| EBIT | -27.15M |
| Earnings Per Share (EPS) | -0.07 |
Balance Sheet
PHAXIAM Therapeutics S.A. holds 38.83M in cash and equivalents against 13.57M in total debt, resulting in a net debt position of -28.68M. Total book value stands at 2.87M, with working capital of 30.96M providing operational flexibility.
| Cash & Cash Equivalents | 38.83M |
| Total Debt | 13.57M |
| Net Debt | -28.68M |
| Equity (Book Value) | 2.87M |
| Book Value Per Share | 0.86 |
| Working Capital | 30.96M |
Stock Splits
PHAXIAM Therapeutics S.A.'s most recent stock split took place on June 13, 2024 with a 61:66 split ratio.
| Last Split Date | 6/13/2024 |
| Split Ratio | 61:66 |
Scores
PHAXIAM Therapeutics S.A. posts an Altman Z-Score of -0.85, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -0.85 |